Ivabradine Accord (Ivabradine)

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, the electrical pathway that sets the heart’s natural pacemaker activity. By blocking this current, the drug slows the heart rate without affecting contractility or blood pressure, providing targeted rate control for angina and systolic heart failure.

The exact dose of Ivabradine Accord is determined by the prescribing clinician based on the patient’s heart rate, clinical condition, and response to therapy. Physicians typically start with a low dose and may adjust it during follow‑up visits to achieve the desired heart‑rate target.

Safety data for Ivabradine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

To order Ivabradine Accord, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Beta‑blockers lower heart rate by blocking adrenergic receptors, affecting both heart rate and contractility, whereas Ivabradine specifically targets the If channel, reducing heart rate without influencing contractile force or blood pressure. This makes Ivabradine a useful add‑on when beta‑blockers alone do not achieve target heart‑rate control or are not tolerated.

Ivabradine Accord tablets should be stored below 25 °C in their original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not store in a refrigerator or freezer, as temperature extremes can affect tablet integrity.

Ivabradine Accord is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals to ensure consistent absorption.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, worsening heart failure, and rare visual disturbances that may lead to persistent visual loss. Patients should be educated to report any sudden vision changes, dizziness, or unusually slow heartbeats promptly.

Ivabradine Accord is contraindicated in patients with sick‑sinus syndrome, severe hypotension, acute decompensated heart failure, or those taking strong CYP3A4 inhibitors such as ketoconazole or clarithromycin. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of the tablet excipients.